Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

29.43
-0.5200-1.74%
Post-market: 29.430.00000.00%18:28 EDT
Volume:797.12K
Turnover:23.64M
Market Cap:1.72B
PE:-4.13
High:30.00
Open:29.71
Low:29.26
Close:29.95
52wk High:46.00
52wk Low:22.24
Shares:58.31M
Float Shares:51.35M
Volume Ratio:0.79
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1203
EPS(LYR):-7.1203
ROE:-30.20%
ROA:-19.94%
PB:1.44
PE(LYR):-4.13

Loading ...

BRIEF-Agios Pharmaceuticals FY Product Revenue USD 54.028 Million Vs. IBES Estimate USD 45.7 Million

Reuters
·
Feb 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 11

Agios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness

Simply Wall St.
·
Feb 06

Earning Preview: Agios Pharmaceuticals revenue is expected to increase by 28.81%, and institutional views are cautiously optimistic

Earnings Agent
·
Feb 05

Agios Pharmaceuticals Inc. to Report Financial Results and Business Highlights

Reuters
·
Jan 26

Is Agios Pharmaceuticals (AGIO) Pricing Reflect Its Recent Rebound And Long Term Track Record

Simply Wall St.
·
Jan 23

Agios Pharma (AGIO) Gets a Buy from TD Cowen

TIPRANKS
·
Jan 14

Agios Pharmaceuticals to Present Strategic Update at J.P. Morgan Healthcare Conference

Reuters
·
Jan 12

Agios Pharmaceuticals Announces 2026 Strategic Priorities Including AQVESME™ U.S. Thalassemia Launch, Planned Regulatory Submission for Sickle Cell Disease, and Advancement of Rare Disease Pipeline Toward Projected $1 Billion Peak Sales

Reuters
·
Jan 12

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

THOMSON REUTERS
·
Jan 12

Agios Pharmaceuticals Inc - Pre-Snda Meeting for Mitapivat in Sickle Cell Disease Anticipated in Q1 2026

THOMSON REUTERS
·
Jan 12

Agios Pharmaceuticals: Expects to Initiate Phase 1B Proof-of-Mechanism Trial of Ag-181 With Pku in H1 2026, Confirm Proof of Mechanism in H2 2026

THOMSON REUTERS
·
Jan 12

Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow Jones
·
Jan 07

BofA Adjusts Price Target on Agios Pharmaceuticals to $35 From $34, Maintains Buy Rating

MT Newswires Live
·
Jan 06

U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure

Reuters
·
Jan 06

Agios Pharmaceuticals CEO Brian Goff Reports Disposal of Common Shares

Reuters
·
Jan 03

Agios Pharmaceuticals Inc : Leerink Partners Raises Target Price to $40 From $34

THOMSON REUTERS
·
Dec 26, 2025

Goldman Sachs Raises Agios (AGIO.US) Price Target to $28, Bullish on Thalassemia Drug Aqvesme's Launch Prospects

Stock News
·
Dec 26, 2025

Agios Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 26, 2025

Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal

MT Newswires Live
·
Dec 25, 2025